Deals
Glaxo Buys Okairos for $324 Million to Grow in Vaccines
This article is for subscribers only.
GlaxoSmithKline Plc acquired Okairos AG, a Swiss developer of vaccine technologies, for 250 million euros ($324 million) to expand its range of inoculations.
The all-cash purchase also includes early-stage products targeting respiratory syncytial virus, hepatitis C virus, malaria, tuberculosis, ebola and HIV, London-based Glaxo said in a statement today. The experimental vaccines for malaria and hepatitis C are in the second of three stages of testing usually required for regulatory approval.